EGFR TKI (3rd generation) · small molecule
rezivertinib
0 active trials across 2 of our biomarkers, targeting EGFR. Not approved for any biomarker on marked.bio yet.
Also known as BPI-7711.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| EGFR exon 19 deletion / L858R | 0 | 3 | – |
| EGFR exon 20 insertion | 0 | 1 | – |
Trials
0 of 3 trials shown
-
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
rezivertinibgefitinib FDA EU
…rollment, a central laboratory testing report has confirmed that the tumor has one of two common EGFR mutations positive that are sensitive to EGFR-TKI therapy, accompanied with or not accompanied with…
EGFR exon 19 deletion / L858REGFR exon 20 insertionNSCLC
-
A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive
…al diagnosis of NSCLC) known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).
EGFR exon 19 deletion / L858RNSCLC
-
BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer
…FR positive gene mutation sensitive to EGFR-TKI treatment (including G719X, exon 19 loss, L858R, L861Q etc.).
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
No trials match these filters.